Trade Mark Journal No.2026/034 21 August 2026

UK00004429187 11 August 2026 (5,44)

AIRNEXIS

International priority date claimed: 24 February 2026 (United States of America) (99668592)

Class 5: Pharmaceutical preparations and drugs for the treatment, control, prevention, maintenance, and management of inflammatory and respiratory diseases and symptoms in humans; anti-inflammatory and immunomodulatory pharmaceutical compositions; medications for respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, pneumonia, allergic rhinitis, Idiopathic Pulmonary Fibrosis (IPF), bronchiectasis, chronic cough and other pulmonary disorders; pharmaceutical compositions in the form of tablets, capsules, liquids, aerosols, inhalers, creams, ointments, gels, and injectables; fixed-dose combination pharmaceutical preparations for inflammatory and respiratory diseases and symptoms in humans; combination pharmaceutical preparations comprising two or more active ingredients for inflammatory and respiratory diseases and symptoms in humans; pharmaceutical preparations for use in combination therapy for inflammatory and respiratory diseases and symptoms in humans.
Class 44: Research, development, and formulation of pharmaceuticals for inflammatory and respiratory diseases; pharmaceutical formulation services in the field of inflammatory and respiratory diseases.

AirNexis Therapeutics, Inc.

Representative: Abion UK Limited